Statement of no intention to make an offer for Brera Holdings plc (the “Company”)

THIS IS AN ANNOUNCEMENT UNDER RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”). 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

AUSTIN, TX, July 21, 2026 (GLOBE NEWSWIRE) — Forward Industries, Inc. (NASDAQ: FWDI) (“Forward”) confirms that it does not intend to make an offer for the Company.

This announcement is intended to be treated as a statement to which Rule 2.8 of the Irish Takeover Rules applies and, accordingly, Forward and any person acting in concert with it will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules.

Forward reserves (on behalf of Forward and its concert parties) the right to set aside this announcement within the next six months where so permitted under Rule 2.8 (including Rule 2.8(c)(ii)) of the Irish Takeover Rules.

Media Contact


[email protected]

Investor Relations

Elevate IR


[email protected]

Important Notices

Responsibility Statement

The directors of Forward accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Publication on Website

In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Forward Industries, Inc.’s website at www.forwardindustries.com by no later than 12 noon (New York time) on the business day following publication of this announcement. The content of the website referred to in this announcement is not incorporated into, and does not form part of, this announcement.

No offer or solicitation

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction, whether pursuant to this announcement or otherwise. The release, publication or distribution of this announcement in whole or in part in, into or from any jurisdiction may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.



Unity 7 Roadmap Revealed At Unite Seoul

Unity 7 Roadmap Revealed At Unite Seoul

U7 Enables Creators, Teams, And Coding Agents To Collaborate Across The Entire Development Cycle

SEOUL, South Korea–(BUSINESS WIRE)–Today at Unite Seoul, Unity (NYSE: U) announced plans for Unity 7, the next generation authoring platform for developing, deploying, and growing games.

Game creation has evolved, with teams of creators and coding agents now working side by side across every part of the craft. Unity 7 is built for that world, designed as an open, collaborative platform where developers, artists, producers, and coding agents can work together across the full development lifecycle.

Unity 7 works hand-in-hand with the AI tools developers already use, powering progression from idea to playable game faster than ever and helping teams of any size to build, monetize, and grow their games.

Crucially, Unity 7 will not require a traditional upgrade from Unity 6 – no rebuilding, no new language to learn, nothing broken in the transition.

“Game development is changing faster than at any point in history,” said Matt Bromberg, President and CEO, Unity. “The future belongs not to the biggest team, but to those who can use new technology to create something unique and find an audience. Unity 7 is the platform that meets this moment.”

Unity 7 is built on five core pillars:

  • Faster Creation: Built on a modernized core utilizing CoreCLR, Unity 7 accelerates every aspect of the development pipeline. The platform will include a near-instant Play Mode, domain reloads that touch only the code that changed, and shader builds that are up to 90% faster, keeping developers in their creative flow.
  • An Open, Collaborative Ecosystem: Unity 7 opens production to the whole team. A new CLI and public API let artists, producers, and developers validate assets, push builds, and collaborate from their own tools, no full Editor access required, while a free-to-use MCP will connect coding agents directly to Unity.
  • Breakthrough Graphics: New rendering advances, including realtime global illumination through Surface Cache GI, will bring richer, more realistic lighting and visual detail to every platform, powered in part by AI-assisted graphics optimization and scaling from high-end PCs down to mobile devices.
  • Smarter Growth and Monetization: Unity Vector, the AI engine behind Unity Ads, helps grow your audience by matching the right players to the right games. Native direct-to-consumer IAP, no-code webshops, and unified catalogs now also feed purchase data directly back into Vector, helping developers find players, monetize more flexibly, and grow more efficiently as they sell.
  • No Breaking Changes: Unity 7 is a direct continuation of the Unity 6 architecture. The upgrade path requires zero rebuilding; all projects, skills, and code will carry forward smoothly into the next generation.

Unity 7 will enter early Beta testing in December, with the Full Release scheduled for Q1 2027.

For more details on Unity 7 and announcements from Unite Seoul, please visit unity.com/releases/unity-7. Watch the Unity 7 trailer here.

About Unity

Unity (NYSE: U) offers a suite of tools to develop, deploy, and grow games and interactive experiences across all major platforms from mobile, PC, and console, to extended reality (XR). For more information, visit Unity.com.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined under federal securities laws, including, in particular, statements about Unity’s plans, strategies, and objectives. The words “believe,” “may,” “will,” “estimate,” “continue,” “intend,” “expect,” “plan,” “project,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Further information on these and additional risks that could affect Unity’s results is included in our filings with the Securities and Exchange Commission (SEC) which are available on the Unity Investor Relations website. Statements herein speak only as of the date of this release, and Unity assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this publication except as required by law.

Unity media relations
Shirley Chu
[email protected]

KEYWORDS: Europe South Korea United Kingdom Asia Pacific

INDUSTRY KEYWORDS: Entertainment Apps/Applications Technology General Entertainment Mobile Entertainment Software Electronic Games

MEDIA:

Logo
Logo

Magnolia Oil & Gas Corporation Announces Pricing of Public Offering of Class A Common Stock

Magnolia Oil & Gas Corporation Announces Pricing of Public Offering of Class A Common Stock

HOUSTON–(BUSINESS WIRE)–
Magnolia Oil & Gas Corporation (“Magnolia”) announced today the pricing of its previously announced underwritten public offering (the “Offering”) of 46,315,790 shares of its Class A common stock (“Common Stock”) at a price to the public of $23.75 per share. Additionally, Magnolia has granted the underwriters a 30-day option to purchase up to an additional 6,947,368 shares of its Common Stock at the public offering price, less underwriting discounts and commissions.

The closing of the Offering is expected to occur on July 22, 2026, and is conditioned upon the satisfaction of customary closing conditions. Magnolia intends to use the net proceeds from the Offering, together with proceeds from a concurrent issuance by Magnolia Oil & Gas Operating LLC (“Magnolia Operating”) and Magnolia Oil & Gas Finance Corp., each a wholly-owned subsidiary of Magnolia, of new senior notes, borrowings under Magnolia Operating’s revolving credit facility and cash on hand, to fund the cash consideration payable by Magnolia Operating in its acquisition of 100% of the issued and outstanding limited liability company interests of WildFire Intermediate Holdings, LLC from WildFire Energy I LLC (the “Pending Acquisition”).

J.P. Morgan and Goldman Sachs & Co. LLC are acting as the joint book-running managers for the Offering. Citigroup, Wells Fargo Securities, BofA Securities, Capital One Securities, Fifth Third Securities, KeyBanc Capital Markets, MUFG, PNC Capital Markets LLC, Regions Securities LLC, Scotiabank, and Truist Securities are also acting as joint book-running managers.

The Offering is being made pursuant to an effective shelf registration statement on Form S-3, which became effective upon filing with the Securities and Exchange Commission (the “SEC”) on July 20, 2026. The Offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus, copies of which may be obtained on the SEC’s website at www.sec.gov. Alternatively, the joint book-running managers will arrange to send you the preliminary prospectus supplement and related base prospectus if you request them by contacting:

J.P. Morgan

c/o Broadridge Financial Solutions

1155 Long Island Avenue

Edgewood, New York 11717

Email: [email protected]

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Magnolia

Magnolia (MGY) is a publicly traded oil and gas exploration and production company with operations primarily in South Texas in the core of the Eagle Ford Shale and Austin Chalk formations. Magnolia focuses on generating value for shareholders by delivering steady, moderate annual production growth resulting from its disciplined and efficient philosophy toward capital spending. Magnolia strives to generate high pre‐tax margins and consistent free cash flow allowing for strong cash returns to its shareholders.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the completion of the Offering, the Pending Acquisition, Magnolia’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward looking statements. When used in this press release, the words could, should, will, may, believe, anticipate, intend, estimate, expect, project, the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events. Except as otherwise required by applicable law, Magnolia disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Magnolia cautions you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Magnolia, incident to the development, production, gathering and sale of oil, natural gas and natural gas liquids. In addition, Magnolia cautions you that the forward looking statements contained in this press release are subject to the following factors: (i) the expected timetable for completing the Pending Acquisition, the results, effects and benefits of the Pending Acquisition, future opportunities for Magnolia, other plans and expectations with respect to the Pending Acquisition, and the anticipated impact of the Pending Acquisition on the Magnolia’s results of operations, financial position, growth opportunities and competitive position; (ii) the market prices of oil, natural gas, natural gas liquids (“NGLs”), and other products or services; (iii) the supply and demand for oil, natural gas, NGLs, and other products or services, including impacts of actions taken by OPEC and other state-controlled oil companies; (iv) the outcome of any legal proceedings that may be instituted against Magnolia; (v) Magnolia’s ability to realize the anticipated benefits of its acquisitions, which may be affected by, among other things, competition and the ability of Magnolia to grow and manage growth profitably; (vi) legislative, regulatory, or policy changes, including those following the change in presidential administrations; (vii) geopolitical and business conditions in key regions of the world; (viii) cybersecurity threats, including increased use of artificial intelligence technologies; and (ix) the possibility that Magnolia may be adversely affected by other economic, business, and/or competitive factors, including inflation. Should one or more of the risks or uncertainties described in this press release occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in Magnolia’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Magnolia’s SEC filings are available publicly on the SEC’s website at www.sec.gov.

Investors

Tom Fitter

713-331-4802

[email protected]

Media

Art Pike

713-842-9057

[email protected]

Christina Kuhl

713-314-4849

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Energy Other Energy Oil/Gas

MEDIA:

Logo
Logo

IMAX and CGV Continue Partnership With Three IMAX With Laser Locations In Vietnam

IMAX and CGV Continue Partnership With Three IMAX With Laser Locations In Vietnam

HO CHI MINH CITY, Vietnam–(BUSINESS WIRE)–
IMAX Corporation (NYSE: IMAX) and CGV today announced an agreement for the upgrade of three existing CGV/IMAX locations to the new state-of-the-art IMAX® with Laser system across Vietnam. The locations, in Ho Chi Minh City and Hanoi, will be upgraded beginning in 2027, and once complete will bring the CGV/IMAX network in Vietnam entirely onto IMAX with Laser.

“Vietnam has quickly emerged as one of IMAX’s most exciting growth markets in Southeast Asia, driven by a passionate moviegoing audience, a strengthening local-language film industry, and strong demand for the best experiences possible,” said Preetham Daniel, VP, Theatre Development, India, Korea, South East Asia and Australasia at IMAX. “CGV has been an outstanding partner, and upgrading these locations to IMAX with Laser will ensure audiences in Vietnam can experience the crystal-clear image and immersive sound of IMAX.”

This agreement comes on the heels of explosive growth in Vietnam for IMAX. 2025 was the Company’s best year ever in the country with nearly $6 million in box office, driven in part by the first-ever Vietnamese-language IMAX titles; “Money Kisses” and the recent “A Gift From Heaven.” The IMAX network in the country has doubled since 2022, growing to eight locations today with at least three more in backlog, inclusive of this agreement.

The CGV IMAX locations will be equipped with IMAX with Laser, IMAX’s most advanced cinema experience. Developed from the ground up for maximum immersion, IMAX with Laser delivers crystal-clear 4K images, precision audio, and state-of-the-art projection technology, setting a new standard for moviegoing.

About IMAX Corporation

IMAX (NYSE: IMAX) is a global leader in entertainment technology, delivering immersive cinematic experiences through proprietary software, architecture, and projection systems. Filmmakers, studios, and artists worldwide use IMAX to connect with audiences at scale, making its network one of the most powerful platforms for blockbuster events and entertainment.

Headquartered in New York, Toronto, and Los Angeles, IMAX operates 1,865 systems across 91 countries and territories as of March 31, 2026. IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trades on the Hong Kong Stock Exchange under stock code “1970.” IMAX and related marks are trademarks of IMAX Corporation. For more information, visit www.imax.com.

For additional information please contact:

Media:

[email protected]

KEYWORDS: Viet Nam Southeast Asia Asia Pacific

INDUSTRY KEYWORDS: Film & Motion Pictures Audio/Video General Entertainment Technology Entertainment

MEDIA:

Microsoft Platforms Drive AI Modernization in Asia Pacific

Microsoft Platforms Drive AI Modernization in Asia Pacific

Organizations in the region are using Microsoft cloud and AI platforms to unify technologies for secure, resilient operations, ISG Provider Lens® report says

SYDNEY–(BUSINESS WIRE)–
Enterprises across Asia Pacific are increasingly incorporating Microsoft cloud and AI platforms into integrated operating environments as they respond to economic uncertainty, evolving regulations and intensifying competition, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The 2026 ISG Provider Lens® Microsoft AI and Cloud Ecosystem report for Asia Pacific finds that Microsoft platforms and services are playing key roles in a broad transition from infrastructure modernization to AI-enabled business transformation. Across Australia and New Zealand, Southeast Asia and India, organizations are integrating cloud, data and AI capabilities into business processes to improve operational efficiency, strengthen customer engagement and make better use of enterprise information.

“In Asia Pacific, AI has quickly matured from an experimental technology into the driving force of enterprise transformation,” said Michael Gale, partner and regional leader, ISG Asia Pacific. “Enterprises in this market increasingly view the Microsoft ecosystem as strategic to the next phase of modernization.”

Organizations throughout the region are bringing together Microsoft cloud, AI and productivity platforms to create more unified operating environments. Rather than treating AI adoption as a separate initiative, enterprises are embedding AI capabilities into existing business processes to improve everyday operations. This strategy helps to address continuing challenges around fragmented data, legacy infrastructure and growing pressure to demonstrate measurable returns on technology investments. Modern, integrated environments help employees automate routine work, gain access to information and generate insights that support faster, more informed decisions.

Changing enterprise priorities around security, regulation and operational resilience are also influencing Microsoft adoption in Asia Pacific. Organizations are adopting responsible AI practices and secure cloud architectures that comply with evolving data sovereignty requirements. Microsoft is making massive investments to support increased usage in the region, including a $3 billion expansion framework across Asia Pacific and the establishment of the company’s largest regional hyperscale data center in Hyderabad, India. Many enterprises are adapting Microsoft technologies to industry-specific operational needs, including digital public services, financial operations, manufacturing and customer engagement, ISG says.

“Organizations that integrate cloud, data and AI capabilities into a coherent modernization strategy, rather than pursuing them piecemeal, see measurably better outcomes,” said Siddharth Idnani, lead author of the report. “Service providers play a critical role here, helping enterprises embed Microsoft technologies into secure, scalable environments built for the long term.”

The report also explores other trends affecting Asia Pacific enterprises, including the growing use of edge computing with cloud environments and Microsoft’s significant investments in training to address a regional shortage of AI and data engineering talent.

For more insights into AI and cloud challenges in Asia Pacific that are relevant to the Microsoft ecosystem, along with ISG’s advice for overcoming them, see the ISG Provider Lens Focal Points briefing here.

The report evaluates the capabilities of 36 providers across three quadrants: Microsoft Productivity and Business Process Services, Azure Data Transformation and AI Services and Azure Managed Services.

It names Accenture & Avanade, DXC Technology, HCLTech, Infosys, Kyndryl, TCS and Wipro as Leaders in all three quadrants. Cognizant, Macquarie Cloud Services and Telstra are named as Leaders in two quadrants each. Fujitsu and NTT DATA are named as Leaders in one quadrant each.

In addition, Cognizant and LTM are named as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant each.

A customized version of the report is available from Informotion.

In the area of customer experience, Wipro is named the global ISG CX Star Performer for 2026 among Microsoft ecosystem providers. Wipro earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

The 2026 ISG Provider Lens Microsoft AI and Cloud Ecosystem report for Asia Pacific is available to subscribers or for one-time purchase on this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Laura Hupprich, ISG

+1 203-517-3132

[email protected]

Erik Arvidson, Matter Communications for ISG

+1 978-518-4542

[email protected]

KEYWORDS: Australia/Oceania Australia Asia Pacific

INDUSTRY KEYWORDS: Technology Consulting Security Professional Services Software Networks Data Analytics Data Management Artificial Intelligence

MEDIA:

Logo
Logo

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).


Q2 2026 Highlights

1

  • Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY).
  • Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY.
  • Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income received from Regeneron.
  • United States (U.S.) Food and Drug Administration (FDA) alignment on ProstACT Global Phase 3 study of TLX591-Tx in mCRPC2 to advance to Part 2 in the U.S.3
  • BiPASS™, patient enrollment nearing completion for study of Illuccix® and Gozellix® for initial prostate cancer diagnosis in the pre-biopsy setting4.
  • Regeneron strategic collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies, initially focused on lung cancer.
  • FY 2026 research and development (R&D) expenditure guidance updated to US$230 million to US$270 million, enabled by the Company’s strong commercial performance and the non-refundable payment of US$40 million received from Regeneron.


Q2 2026 Revenue

 Revenue (US$M) Q2 2026 Q2 2025 % Change Q1 2026 % Change
 Group revenue 247 204 21% 230 7%
 Precision Medicine revenue5 202 155 30% 186 9%
 TMS revenue6 45 48 (6)% 44 2%
           


Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA7 imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.”


Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q2 2026 highlights include:

  • TLX591-Tx (lutetium (177Lu) rosopatamab tetraxetan): Achieved key regulatory milestone for ProstACT Global Phase 3 trial, with the FDA confirming that the safety data from Part 1 of the study of Telix’s lead prostate cancer therapy candidate is sufficient to enable progression of Part 2 in the U.S. The FDA and Telix also achieved alignment on the Part 2 clinical trial protocol, statistical analysis plan, and ongoing safety monitoring plan. Initiation of Part 2 in the U.S. remains subject to the FDA’s review of an Investigational New Drug (IND) amendment8. Part 2 continues to enroll strongly in regions where recruitment is open including Australia, New Zealand, Canada, Türkiye, the United Kingdom, Singapore and South Korea and has also received regulatory approval to commence in China.
  • TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA): OPTIMAL-PSMA study evaluating TLX597-Tx for mCRPC has recently completed patient enrollment of 120 patients9. Building on initial findings of the OPTIMAL-PSMA study, the first patients have been dosed in the OPTIMAL-e Phase 2 study, evaluating TLX597-Tx for metastatic hormone sensitive prostate cancer10. TLX597-Tx is a next generation small molecule PSMA-targeting prostate cancer radioligand therapy (RLT) candidate designed to improve efficacy and quality of life in earlier-stage metastatic prostate cancer.
  • TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan): Dosed first patient in LUTEON11, a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC12. LUTEON will evaluate the efficacy of TLX250-Tx compared with investigator’s choice of monotherapy consistent with standard of care. LUTEON forms part of Telix’s global development program13 for TLX250-Tx, Part 1 is expected to enroll up to 40 patients.
  • TLX101-Tx (131I-iodofalan): Enrolled first patient cohort in Part 1 (assessing safety and dose optimization) of IPAX BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma14. The trial is open for enrollment in Australia, Austria, the Netherlands and Belgium, with approval being sought in additional jurisdictions. Completed patient enrollment in IPAX-215, a Phase 1 study evaluating TLX101-Tx in patients with newly diagnosed glioblastoma, with no dose-limiting toxicities observed to date16.


Precision Medicine Business Unit


PSMA


imaging portfolio:

Telix’s Precision Medicine business continues to expand its commercial reach and support broader patient access to PSMA-PET/CT imaging17. Q2 2026 highlights include:

  • Rapid enrollment of 338 patients in BiPASS™ Phase 3 study of Illuccix and Gozellix for the initial diagnosis of prostate cancer, integrating non-invasive 68Ga-PSMA-11 PET imaging prior to biopsy. Building on the clinical foundation established by the PRIMARY18 and PRIMARY 219 studies, BiPASS™ is intended to support regulatory submissions in major markets, including the U.S., Europe and Australia.
  • Completed patient enrollment in Japan in Phase 3 registrational study of TLX591-Px (Illuccix)20. Telix is preparing a New Drug Application (NDA) for submission in Japan, with clinical data from the Phase 3 local study intended to support the application. In parallel, Telix’s application for Conditional Approval is under review by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). If granted, Conditional Approval will enable an expedited NDA review process while the final study clinical dataset is prepared.


TLX101-Px, (Floretyrosine F 18 or 18F-FET) for brain cancer imaging:

  • Submitted an IND application to the FDA for Pixclara®, a Phase 3 registrational study for indication expansion for the diagnosis of brain metastases.
  • The FDA has accepted Telix’s resubmitted NDA for Pixclara®21 and has granted a PDUFA22 goal date of September 11, 202623.
  • Telix’s Marketing Authorization Application (MAA) for Pixlumi®21 in Europe has been validated and accepted for review24.


Zircaix®


21


(TLX250-Px, 89Zr-DFO-girentuximab) for kidney cancer imaging:

  • Telix continues to make good progress on its Biologics License Application (BLA) resubmission for Zircaix®21 in the U.S. Final Chemistry, Manufacturing and Controls (CMC) documentation is nearing completion. Consistent with TLX250-Px’s Breakthrough Therapy designation, Telix has maintained regular consultation with the FDA and expects to resubmit the application shortly.


Telix Manufacturing Solutions (TMS): Expanded global operations

TMS continues to expand its global operations which are fundamental to Telix’s future growth, supporting supply chain resilience. Q2 2026 highlights include:

  • Opened TMS North Melbourne, in partnership with the Melbourne Theranostic Innovation Centre (MTIC)25. The purpose-built facility combines radiochemistry laboratories, clinical product manufacturing, patient dosing and imaging that aims to provide advanced clinical infrastructure and R&D capabilities to accelerate the development of targeted radiopharmaceuticals.
  • TMS Brussels South successfully completed its first Good Manufacturing Practice (GMP) production run of a lutetium-based therapeutic candidate, representing a significant operational milestone and further validating the facility’s capabilities to support the manufacture of Telix’s next-generation therapeutics.
  • Installed ARTMS’ QUANTM® Irradiation System (QIS®) at TMS Yokohama, expanding isotope production capabilities and enabling local Zirconium-89 (89Zr) manufacturing to support Telix’s portfolio. The installation represents further progress in scaling the ARTMS network and advancing toward the Company’s target of 50 QIS® installations globally by the end of 2026.


Corporate Updates

Telix entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies26. The strategic partnership combines Telix’s radiopharmaceutical development, manufacturing and supply chain capabilities with Regeneron’s leading antibody discovery and development platforms, creating a framework to advance multiple novel oncology programs and further strengthen Telix’s position in Precision Medicine. On execution of the agreement, Telix has received an initial non-refundable payment from Regeneron of US$40 million.

Telix also completed a refinancing of its existing convertible bond structure, issuing US$600 million of new convertible bonds due 2031 and repurchasing all outstanding 2029 convertible bonds27. The transaction extends debt maturities, enhances financial flexibility and further strengthens the Company’s capital structure, supporting the execution of Telix’s long-term growth strategy, including developing its late-stage therapeutics pipeline.

Three new Non-Executive Directors were appointed during the quarter as part of Telix’s Board expansion and succession planning. Effective May 11, 2026, David Gill, Maria Rivas, MD, and William Jellison28 joined the Board, further strengthening the Board’s clinical, commercial, financial and governance expertise, enhancing the Company’s capabilities as a dual-listed, commercial stage biopharmaceutical company.


FY 2026 guidance

  • Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income from Regeneron.
  • Revenue guidance reflects product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.
  • Telix has updated FY 2026 R&D expenditure guidance to US$230 million to US$270 million, subject to achieving ongoing global clinical data outcomes and development milestones. The additional investment will support the advancement of high-value clinical programs beyond the Company’s original R&D forecast, including acceleration of the TLX597-Tx program and label expansion for Pixclara®, and progression of the Regeneron strategic collaboration.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. FDA. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction. The Company’s late-stage therapeutic pipeline includes three assets in pivotal-stage trials – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (131I-iodofalan) in recurrent glioblastoma, TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, complemented by a deep pipeline of next generation assets.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations

Annie Kasparian

[email protected]

Charlene Jaw

[email protected]

Media

Eliza Schleifstein

[email protected]

   

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

1 The financial information for the quarter ended June 30, 2026 is unaudited.
2 Metastatic castration-resistant prostate cancer.
3 Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345.
4 ClinicalTrials.gov ID: NCT07052214.
5 Primarily sales of Illuccix and Gozellix in our Precision Medicine business.
6 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS), excludes Illuccix and Gozellix sales and TMS inter-segment revenue.
7 Prostate-specific membrane antigen.
8 Telix ASX disclosure July 2, 2026.
9 Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.
10 Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336.
11 Telix media release July 21, 2026. ClinicalTrials.gov ID: NCT07197580.
12 Clear cell renal cell carcinoma.
13 Telix’s global development program for TLX250-Tx includes the separate LUTEON ATLAS study in the U.S. and Europe.
14 ClinicalTrials.gov ID: NCT07100730.
15 ClinicalTrials.gov ID: NCT05450744.
16 Telix media release May 19, 2026.
17 Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography.
18 Emmett et al. Eur Urol. 2021.
19 Buteau et al. Lancet Oncol. 2026. ClinicalTrials.gov ID: NCT05154162.
20 Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473.
21 Brand name subject to final regulatory approval.
22 Prescription Drug User Fee Act.
23 Telix ASX disclosure April 10, 2026.
24 Telix media release May 1, 2026.
25 Telix media release July 16, 2026.
26 Telix ASX disclosure April 13, 2026.
27 Telix ASX disclosure April 23, 2026.
28 Telix ASX disclosure April 2, 2026. Telix ASX disclosure April 9, 2026.



Cementos Pacasmayo S.A.A. Announces Consolidated Results for Second Quarter 2026

Cementos Pacasmayo S.A.A. Announces Consolidated Results for Second Quarter 2026

LIMA, Peru–(BUSINESS WIRE)–
Cementos Pacasmayo S.A.A. and subsidiaries (NYSE: CPAC; BVL: CPACASC1) (“the Company” or “Pacasmayo”) a leading cement company serving the Peruvian construction industry, announced today its consolidated results for the second quarter (“2Q26”) and the first six months of the year (“6M26”). These results have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and are stated in Soles (S/).

2Q26 FINANCIAL AND OPERATIONAL HIGHLIGHTS:

(All comparisons are to 2Q25, unless otherwise stated)

  • Sales volume of cement, concrete and precast increased by 15.5%, mainly due to an increase in bagged cement demand, as self-construction continued its strong performance.
  • Revenues increased by 15.4%, in line with the increased sales volumes mentioned above.
  • Consolidated EBITDA increased 34.3%, reaching S/174.8 million, mainly due to the above-mentioned sales volume increase, as well as higher operating profit as profitability in the concrete sector increased.
  • Consolidated EBITDA margin was 31.3%, a 4.4 percentage point increase.
  • Net income was S/ 77.2 million, a 61.5% increase, mainly due to higher operating income as well as lower financial expenses as debt levels continued decreasing.

6M26 FINANCIAL AND OPERATIONAL HIGHLIGHTS:

(All comparisons are to 6M25, unless otherwise stated)

  • Sales volume increased by 13.6%, mainly due to increased demand for bagged cement, as mentioned above.
  • Revenues increased by 13.3%, in line with the increased sales volume.
  • Consolidated EBITDA increased 33.1%, reaching S/352.7 million, mainly due to increased demand, as well as operational efficiencies from higher-margin concrete products.
  • Consolidated EBITDA margin was 31.6%, a 4.7 percentage point increase.
  • Net income increased by 58.4%, reaching S/ 159.2 million mainly due to higher operating income, as well as slightly lower financial expenses as we continue to lower our debt levels.

For a full version of Cementos Pacasmayo’s Second Quarter 2026 Earnings Release, please visit https://www.cementospacasmayo.com.pe/inversionistas/reportes

CONFERENCE CALL INFORMATION:

Cementos Pacasmayo will host a conference call on Tuesday, July 21, 2026, to discuss these results at 9:30 a.m. Lima Time/ 10:30 a.m. Eastern Time.

To access the call, please dial:

+1 (718) 866-4614 from within the U.S.

Access code: 505256

There will also be a live Audio Webcast of the event at:

https://mm.closir.com/slides?id=505256

You can also find additional dial-in numbers depending on your current location in the above link.

About Cementos Pacasmayo S.A.A.

Cementos Pacasmayo S.A.A. a member of the Holcim Group, is a cement company, located in the Northern region of Peru. In February 2012, the Company’s shares were listed on The New York Stock Exchange – Euronext under the ticker symbol “CPAC”. With almost 70 years of operating history, the Company produces, distributes and sells cement and cement-related materials, such as ready-mix concrete and precast materials. Pacasmayo’s products are primarily used in construction, which has been one of the fastest-growing segments of the Peruvian economy in recent years. The Company also produces and sells quicklime for use in mining operations.

Cementos Pacasmayo S.A.A.

In Lima, Peru:

Ely Hayashi, CFO

Claudia Bustamante

Sustainability and IR Managing Director

+51-958699760

[email protected]

KEYWORDS: New York Latin America North America United States Peru South America

INDUSTRY KEYWORDS: Mining/Minerals Other Construction & Property Manufacturing Natural Resources Construction & Property Building Systems Other Manufacturing

MEDIA:

Columbia Financial, Inc. Announces Completion of Second Step Conversion and $1.7 Billion Stock Offering and Acquisition of Northfield Bancorp, Inc.

FAIR LAWN, N.J., July 20, 2026 (GLOBE NEWSWIRE) — Columbia Financial, Inc., (Nasdaq Global Select Market: CLBK), (the “Company” or “Columbia”), a Maryland corporation and the successor to Columbia Financial, Inc., a Delaware corporation (the “Holding Company”), today announced the completion of the Holding Company’s conversion from the mutual holding company structure and Company’s related public offering. Columbia Bank is now 100% owned by the Company and the Company is 100% owned by public stockholders.

The Company also announced today that, simultaneously with the completion of the conversion, it has completed its previously announced merger with Northfield Bancorp, Inc. (“Northfield”). Subsequent to the closing, on a pro forma basis as of March 31, 2026, Columbia had $18.0 billion in total assets, $12.5 billion in total deposits and $11.9 billion in total loans held for investment and more than 100 branch offices throughout New Jersey and in Staten Island and Brooklyn, New York. Northfield’s subsidiary bank, Northfield Bank, was merged into Columbia Bank.

“We are very pleased to announce the completion of our second-step conversion and merger with Northfield. The combination of our two organizations creates one of the largest community banks headquartered in the region, with substantial excess capital to support growth, strengthen our market position and create long-term value,” said Thomas J. Kemly, President and Chief Executive Officer of Columbia.   “Columbia and Northfield share proud histories as community banks built on strong relationships, local decision-making and a deep commitment to the communities we serve. Together, we are better positioned to deepen customer relationships, support our commercial customers and expand across a larger, more dynamic market, while continuing to deliver the local service and community focus that have long defined both institutions.”

“Over the past five months, the Columbia and Northfield teams have worked diligently to bring together two highly respected community banking organizations. Today marks the successful completion of that effort and the beginning of an exciting new chapter. With a shared commitment to our customers, team members, communities, and stockholders, we have created a stronger institution with the scale, talent, and financial strength to deliver greater value and drive long-term growth. This combination positions us for continued success in one of the most attractive banking markets in the country,” said Steven M. Klein, Chairman, President and Chief Executive Officer of Northfield.  

The Company sold 167,236,353 shares of common stock at a purchase price of $10.00 per share in the stock offering. Concurrent with the completion of the conversion and stock offering, each share of Holding Company common stock owned by public stockholders was exchanged for 2.2000 shares of Company common stock. Cash in lieu of fractional shares will be paid at a rate of $10.00 per share.

Under the terms of the merger agreement, each share of Northfield common stock was converted into the right to receive either $14.25 in cash or 1.425 shares of Company common stock, or a combination thereof, subject to the elections made and proration procedures, for an aggregate transaction value of $580 million. Northfield stockholders who did not make an election (“non-election shares”) will receive cash consideration of $8.06 and 0.6185 of a share of Company common stock for each non-election share of Northfield common stock held by such stockholders based on the proration procedures in the merger agreement. Final aggregate merger consideration at closing will be comprised of 70% Company common stock and 30% cash. Cash in lieu of fractional shares will be paid at a rate of $10.00 per share.

In accordance with the merger agreement, John P. Connors, Jr., Timothy C. Harrison, Steven M. Klein and Paul V. Stahlin, all of whom served as directors of Northfield, have been appointed to the Boards of Directors of the Company and Columbia Bank, effective as of the effective time of the merger. In addition, Mr. Klein was appointed as Senior Executive Vice President, Chief Operating Officer of the Company and the Bank.

After the issuance of shares in the conversion and the acquisition and adjustments for cash payments in lieu of fractional shares, Columbia will have approximately 269,542,256 shares of common stock outstanding. Shares of the Company’s common stock will begin trading on the NASDAQ Global Select Market on Tuesday, July 21, 2026, under the symbol “CLBK,” CUSIP No. 197914104. If you subscribed for shares of the Company’s common stock in the subscription offering and have any questions regarding your subscription order, you may confirm your subscription order online at https://allocations.kbw.com, or you may contact the Stock Information Center at (844) 265-9680. Additionally, purchasers in the subscription offering who have questions about their Direct Registration System (“DRS”) Book-Entry statements, as well as interest checks, should contact Broadridge Corporate Issuer Solutions, LLC after the closing date at (800) 586-1549. Statements reflecting ownership of shares of common stock purchased in the subscription offering are expected to be mailed to subscribers on or about July 23, 2026.

Current owners of the Holding Company’s stock holding shares in street name or in book-entry form will receive shares of Company common stock in their accounts.  Current owners of the Holding Company’s stock holding shares in certificate form will be mailed a letter of transmittal following the closing of the transaction and will receive ownership statements reflecting their shares of Company common stock and cash in lieu of fractional shares after returning their stock certificates and a properly completed letter of transmittal to the Company’s transfer agent. Current owners of the Holding Company’s stock or current Northfield stockholders who hold their shares directly as the record holder and have any questions about their accounts should contact the Company’s transfer agent Broadridge Financial Solutions, LLC at (877) 830-4932. Existing stockholders of the Holding Company or Northfield whose shares are beneficially held in “street name” should contact their broker-dealer or other nominee with any questions about their accounts.

Keefe, Bruyette & Woods, Inc., A Stifel Company, acted as selling agent for the subscription portion of the offering and served as the lead-left book running manager for the firm commitment offering. Piper Sandler & Co. acted as co-book running manager for the firm commitment offering and Brean Capital, LLC acted as co-manager.

Kilpatrick Townsend & Stockton LLP served as legal counsel to the Company and the Holding Company for the conversion, Nutter McClennen & Fish LLP served as legal counsel to Keefe, Bruyette & Woods, Inc., A Stifel Company and the underwriters. RP Financial, LC., served as independent appraiser for the conversion and offering.     

Kilpatrick Townsend & Stockton LLP served as legal counsel to Columbia for the merger and Keefe, Bruyette & Woods, Inc., A Stifel Company, acted as financial advisor to Columbia. Luse Gorman, PC served as legal counsel to Northfield for the merger and Raymond James acted as financial advisor to Northfield.

About Columbia

The Company is a Maryland corporation organized as Columbia Bank’s stock holding company. Columbia Bank is a federally chartered savings bank headquartered in Fair Lawn, New Jersey that operates over 100 full-service banking offices and offers traditional financial services to consumers and businesses in its market area. For more information about Columbia Bank, please visit www.columbiabankonline.com.

Disclaimer and Caution About Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Columbia, respectively, with respect to the proposed transaction, the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company’s future financial performance (including anticipated accretion to earnings per share, the tangible book value earn-back period and other operating and return metrics), the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses. Such statements are often characterized by the use of qualified words (and their derivatives) such as “may,” “will,” “anticipate,” “could,” “should,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “project” and “intend,” as well as words of similar meaning or other statements concerning opinions or judgment of Columbia and its management about future events.

Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements. Such risks, uncertainties and assumptions, include, among others, the following: (i) the outcome of any legal proceedings that may be instituted against Columbia; (ii) the possibility that the anticipated benefits of the proposed transaction, including anticipated cost savings and strategic gains, are not realized when expected or at all, including as a result of changes in, or problems arising from, general economic and market conditions, interest and exchange rates, monetary policy, laws and regulations and their enforcement, and the degree of competition in the geographic and business areas in which the combined operates ; (iii) the possibility that the integration of the two companies may be more difficult, time-consuming or costly than expected; (iv) the impact of purchase accounting with respect to the proposed transaction, or any change in the assumptions used regarding the assets acquired and liabilities assumed to determine their fair value and credit marks; (v) the diversion of management’s attention from ongoing business operations and opportunities; (vi) potential adverse reactions of Columbia’s customers (including former Northfield customers) or changes to business or employee relationships, including those resulting from the completion of the proposed transaction; (vii) a material adverse change in the financial condition of Columbia; (vii) changes in Columbia’s share price following the closing of the conversion and offering; (viii) risks relating to the potential dilutive effect of shares of Columbia’s common stock to be issued in the proposed transaction; (ix) general competitive, economic, political and market conditions, including the impact of any potential government shutdown; (x) major catastrophes such as earthquakes, floods or other natural or human disasters, including infectious disease outbreaks; and (xi) other factors that may affect future results of Columbia, including, among others; changes in asset quality and credit risk; the imposition of tariffs and any retaliatory responses; the inability to sustain revenue and earnings growth; changes in interest rates; deposit flows; inflation; customer borrowing, repayment, investment and deposit practices; the impact, extent and timing of technological changes; capital management activities; and other actions of the Federal Reserve Board and legislative and regulatory actions and reforms.

These factors are not necessarily all of the factors that could cause the combined company’s actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm the combined company’s results.

Although Columbia believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions based on its existing knowledge of its business and operations, there can be no assurance that actual results of Columbia will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in Columbia’s most recent annual report on Form 10-K for the fiscal year ended December 31, 2025, quarterly reports on Form 10-Q, and other documents subsequently filed by Columbia with the Securities Exchange Commission. The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Columbia or its businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Columbia urges you to consider all of these risks, uncertainties and other factors carefully in evaluating all such forward-looking statements made by Columbia. Forward-looking statements speak only as of the date they are made and Columbia undertakes no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.   For purposes of this section, references to Columbia include both the Company and the Holding Company.

Columbia Financial, Inc.

Investor Relations Department

(833) 550-0717



UK Government pledges broad package to anchor Vertical’s first full-scale production sites in the UK

UK Government pledges broad package to anchor Vertical’s first full-scale production sites in the UK

  • Vertical and UK Government are in advanced discussions on a broad package to anchor the first of Vertical’s planned global full-production sites in the UK

  • Package would include a further grant of up to £10 million ($13.5 million), bringing total direct UK Government funding support to approximately £48 million ($64 million)

  • Also includes wider engagement and financial support across defence, export finance, future flight and dual-use innovation

  • Vertical is now progressing UK sites down-selection for the first of its global full production aircraft assembly and battery manufacturing facilities

  • Vertical and UK Export Finance sign Memorandum of Understanding to establish a framework for future export and customer financing cooperation

  • UK production is expected to create 700 direct, highly skilled jobs outside London by 2030, with Frontier Economics estimating up to 2,200 new jobs and £3 billion in annual GVA by 2035

LONDON & NEW YORK–(BUSINESS WIRE)–
Vertical Aerospace (“Vertical” or the “Company”) (NYSE:EVTL), a global aerospace and technology company that is pioneering electric aviation, today announced that it is in advanced discussions with the UK Government on a package of support to anchor the first of its planned global full-production sites in the United Kingdom. The Company is now progressing UK site down-selection for its Valo electric vertical take-off and landing (eVTOL) aircraft assembly and battery manufacturing facilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720515478/en/

UK Government announcement comes a day after Vertical Aerospace flew the first piloted eVTOL aircraft at Farnborough International Airshow

UK Government announcement comes a day after Vertical Aerospace flew the first piloted eVTOL aircraft at Farnborough International Airshow

The package includes grant funding of up to £10m ($13.5m) in connection with Vertical finalising the down-selection of UK sites for its aircraft and battery facilities.

Vertical is now working toward a final siting decision, expected before the end of the year. Locating production in the UK will also streamline certification, with Vertical’s design and production organisation approvals located under the same regulatory framework with the UK Civil Aviation Authority (CAA).

The package also includes a commitment to establish a broad, cross-government programme to back Vertical’s transition from prototype development to industrial scale-up, including:

  • confirmed interest from the Ministry of Defence in the defence applications for Vertical’s eVTOL, hybrid-electric and autonomous capabilities, with ongoing engagement to explore dual-use opportunities

  • signed Memorandum of Understanding between Vertical and UK Export Finance to establish a framework for offering export-linked and customer financing facilities as Vertical fulfils its commercial pipeline

  • continued support from Innovate UK, as part of the UK’s future of aviation, focusing on high-potential businesses like Vertical and helping the transition from prototype to commercialisation and growth

Vertical’s first full-scale aircraft final assembly and battery manufacturing facilities are expected to support around 700 direct jobs by 2030, alongside wider benefits for the UK aerospace supply chain, industrial capability and future aviation ecosystem.

The announcement builds on longstanding UK Government backing for Vertical through the Aerospace Technology Institute (ATI) programme and the Future Flight Challenge, which have helped the Company progress from early-stage technology development toward certification and industrialisation. With this package, direct UK Government grant support awarded to Vertical would total up to £48 million ($64 million).

Stuart Simpson, CEO of Vertical Aerospace, said:

“This is a major vote of confidence from the UK Government in Vertical, in our aerospace sector and in the UK’s opportunity to lead the next generation of aviation. The UK has backed us from the earliest stages of the programme, and today’s proposed support helps create a clear pathway from innovation to industrial scale-up. It means we will continue to create high-value jobs, strengthen Britain’s advanced manufacturing base, and build aircraft that will be exported to customers around the world. We are grateful for that backing and committed to building the future of electric flight here in the UK.”

The aircraft is expected to be the first all-new aircraft designed and built in the UK in more than three decades. The UK is uniquely well-placed to benefit from the growth of advanced air mobility, with strong aerospace capability, a supportive regulator in the CAA, world-class engineering talent and a deep supply chain.

The Department for Business and Trade grant of up to £10 million remains subject to the completion of legal, subsidy control, due diligence and ministerial approval processes, and the Memorandum of Understanding with UK Export Finance is not legally binding.

About Vertical Aerospace

Vertical Aerospace is a global aerospace and technology company pioneering electric aviation. Vertical is creating a safer, cleaner, and quieter way to travel. Valo is a piloted, four-passenger, Electric Vertical Take-Off and Landing (eVTOL) aircraft, with zero operating emissions. Vertical is also developing a hybrid-electric variant, offering increased range and mission flexibility to meet the evolving needs of the advanced air mobility market.

Vertical combines partnerships with leading aerospace companies, including Honeywell, Syensqo and Sonaca, with its own proprietary battery and propeller technology to develop the world’s most advanced and safest eVTOL.

Vertical has c.1,500 pre-orders of Valo, with customers across four continents, including American Airlines, Avolon, Bristow, GOL and Japan Airlines. Certain customer obligations are expected to be fulfilled via third-party agreements. Headquartered in Bristol, UK, Vertical’s experienced leadership team comes from top-tier aerospace and automotive companies such as Rolls-Royce, Airbus, GM, and Leonardo. Together, they have previously certified and supported over 30 different civil and military aircraft and propulsion systems.

Forward looking statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding a UK Government package to support the Company’s planned global full-production sites in the United Kingdom, which remains subject to the completion of legal, subsidy control, due diligence and ministerial approval processes; the Memorandum of Understanding from UK Export Finance, which is not legally binding; the interest from the Ministry of Defence in the defence applications for Vertical’s eVTOL, hybrid-electric and autonomous capabilities; the continued support from Innovate UK; the business strategy and plans and objectives of management for future operations, including the Company’s plans for certification, industrialisation and commercialisation of the Valo aircraft and the hybrid-electric Valo variant and our ability to achieve regulatory certification of our aircraft product on any particular timeline or at all, the plans around the development and testing of the hybrid-electric Valo variant, the design and manufacture of our aircrafts, the features and capabilities of our aircrafts, selection of suppliers, expectations surrounding pre-orders and commitments; statements and projections contained in the Frontier Economics report which was commissioned by Vertical and based on Vertical-supplied data, including management projections, assumptions, targets, expectations and estimates in which actual results may vary due to a number of risks and uncertainties relating to the business, industry performance, the regulatory environment, and general business and economic conditions; as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate,” “will,” “aim,” “potential,” “continue,” “is/are likely to” and similar statements of a future or forward-looking nature. These forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”) on March 24, 2026, as such factors may be updated from time to time in the Company’s other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

For more information:

Vertical Aerospace Media:

Justin Bates, Head of Communications

[email protected]

+44 7878 357 463

Vertical Aerospace Investor Relations:

Gillian Levine, Investor Relations Lead

[email protected]

+1 248 470 8732

KEYWORDS: New York Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Transportation Travel Packaging Engineering Air Aerospace Transport Manufacturing

MEDIA:

Photo
Photo
UK Government announcement comes a day after Vertical Aerospace flew the first piloted eVTOL aircraft at Farnborough International Airshow
Logo
Logo

Quantum BioPharma Announces Intention to Settle Debt

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, July 20, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates:

The Company announces that its board of directors has approved the settlement of CAD$123,487.43 owing to arm’s length creditors and insiders of the Company (collectively, the “Creditors”) through the issuance of Class B subordinate voting shares in the capital of the Company (“Class B Shares”) at a deemed price per Class B Share based on the lower of: (i) CAD$4.26; and (ii) the closing price of the Class B Shares on the Canadian Securities Exchange (the “CSE”) on the trading day immediately prior to the date of the closing of the Debt Settlement (the “Debt Settlement”).

The securities issued pursuant to the Debt Settlement have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd ™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.

Forward-Looking Information

This news release contains “forward-looking statements” or “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. Forward-looking statements include, but are not limited to, statements regarding: the expected timing for completion of the Offering and the intended use of proceeds.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements are highlighted in the “Risks and Uncertainties” in the Company’s management discussion and analysis.

Forward-looking statements are based upon a number of estimates and assumptions that, while considered reasonable by the Company at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies that may cause the Company’s actual financial results, performance, or achievements to be materially different from those expressed or implied herein. Some of the material factors or assumptions used to develop forward-looking statements include, without limitation: the failure to complete the Offering; reliance on key management and other personnel; potential downturns in economic conditions; competition from others; market factors, including future demand products developed by the Company; the policies and actions of foreign governments, which could impact the ability of the Company to successfully market its products; the Company’s expectations in connection with the development of the Target Acquisition System; the effectiveness of the Target Acquisition System; changes in national and local government legislation, taxation, controls or regulations and/or changes in the administration or laws, policies and practices; the impact of general business and economic conditions; currency exchange rates; and the impact of inflation.

The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Any forward-looking statements and the assumptions made with respect thereto are made as of the date of this news release and, accordingly, are subject to change after such date. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]
Telephone: (833) 571-1811

Investor Relations
Email: [email protected], [email protected]
Website: www.quantumbiopharma.com